Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial

Trials. 2020 Jun 16;21(1):536. doi: 10.1186/s13063-020-04504-x.

Authors

Christina M Eckhardt¹, Matthew J Cummings², Kartik N Rajagopalan², Sarah Borden², Zachary C Bitan², Allison Wolf², Alex Kantor², Thomas Briese², Benjamin J Meyer², Samuel D Jacobson², Dawn Scotto², Nischay Mishra², Neena M Philip², Brie A Stotler², Joseph Schwartz², Beth Shaz², Steven L Spitalnik², Andrew Eisenberger², Eldad A Hod², Jessica Justman², Ken Cheung², W Ian Lipkin², Max R O'Donnell²

Affiliations

¹ Columbia University Medical Center, New York, USA. cme2113@cumc.columbia.edu.
² Columbia University Medical Center, New York, USA.

Abstract

An amendment to this paper has been published and can be accessed via the original article.

Publication types

Published Erratum